The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia

Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036

(2011) Wayne W. Chan et al.   CANCER CELL

The ABL Switch Control Inhibitor DCC-2036 Is Active against the Chronic Myeloid Leukemia Mutant BCR-ABLT315I and Exhibits a Narrow Resistance Profile

(2011) C. A. Eide et al.   CANCER RESEARCH

Successful treatment using omacetaxine for a patient with CML and BCR-ABL1 35INS

(2010) K. M. Mahadeo et al.   BLOOD

ABL Alternative Splicing Is Quite Frequent in Normal Population - Letter

(2010) I. Santamaria et al.   MOLECULAR CANCER THERAPEUTICS

Variant Isoforms of BCR-ABL1 in Chronic Myelogenous Leukemia Reflect Alternative Splicing of ABL1 in Normal Tissue - Letter

(2010) J. S. Khorashad et al.   MOLECULAR CANCER THERAPEUTICS

Exon 7 Deletion in the bcr-abl Gene Is Frequent in Chronic Myeloid Leukemia Patients and Is Not Correlated with Resistance against Imatinib

(2010) J.-B. Gaillard et al.   MOLECULAR CANCER THERAPEUTICS

BCR-ABL Truncation due to Premature Translation Termination as a Mechanism of Resistance to Kinase Inhibitors

(2009) Wanlong Ma et al.   ACTA HAEMATOLOGICA

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

(2009) Thomas O'Hare et al.   CANCER CELL

Functional characterization of an activating TEK mutation in acute myeloid leukemia: a cellular context-dependent activating mutation

(2009) J W Tyner et al.   LEUKEMIA

An Intron-Derived Insertion/Truncation Mutation in the BCR-ABL Kinase Domain in Chronic Myeloid Leukemia Patients Undergoing Kinase Inhibitor Therapy

(2008) Jennifer Laudadio et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia

(2008) D W Sherbenou et al.   LEUKEMIA

BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations

(2008) T.-S. Lee et al.   MOLECULAR CANCER THERAPEUTICS